Bactiguard (BACTI) Q4 2024 earnings summary

Executive summary

• License-focused strategy resulted in increased revenues and a return to EBITDA profitability for 2024, with total revenue up 17.3% year-over-year to SEK 261.9 million and net sales up 19.9% to SEK 241.7 million.

• Strategic shift included discontinuing the BIP portfolio and transitioning Foley catheter markets to BD, achieving significant cost savings and improved margins.

• Strengthened organization with key hires in R&D and business intelligence, enhancing regulatory, clinical, and commercial capabilities.

• Technology demonstrated strong clinical efficacy, with recent studies showing approximately 70% infection risk reduction.

• Wound Management portfolio continued stable, profitable growth and expansion in Asia.

Financial highlights

• Full-year 2024 revenues were SEK 261.9 million, up from SEK 223.2 million in 2023; Q4 revenues reached SEK 68.3 million, up 11.3% year-over-year.

• Q4 net sales were SEK 63.1 million, up 12.1% year-over-year; full year net sales totaled SEK 241.7 million, up 19.9%.

• Q4 EBITDA was SEK 8.4 million (margin 12.4%); full year EBITDA was SEK 18.0 million (margin 6.9%), up from SEK -76.1 million in 2023.

• Net loss narrowed to SEK 29.8 million from SEK 138.4 million in 2023.

• Cost savings exceeded SEK 25 million annually, with full year OpEx down 12% to SEK 207.9 million.

• Cash flow from operating activities was SEK 25.0 million for 2024; year-end cash and equivalents stood at SEK 116.7 million.

Outlook and guidance

• Financial targets for 2028 are under review due to the Zimmer Biomet agreement termination; updated guidance expected by end of Q1 2025.

• Focus remains on expanding licensing partnerships and leveraging R&D to secure new agreements, especially in the US and Asia.

• Wound Management portfolio anticipated to maintain stable, profitable growth.

• No dividend proposed for 2024.

• Continued focus on cost control and EBITDA profitability, with ongoing operational discipline.